The EZH2 polycomb transcriptional repressor—a marker or mover of metastatic prostate cancer?
Open Access
- 1 November 2002
- journal article
- review article
- Published by Elsevier in Cancer Cell
- Vol. 2 (5) , 349-350
- https://doi.org/10.1016/s1535-6108(02)00187-3
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Role of Histone H3 Lysine 27 Methylation in Polycomb-Group SilencingScience, 2002
- The polycomb group protein EZH2 is involved in progression of prostate cancerNature, 2002
- A Randomized Trial Comparing Radical Prostatectomy with Watchful Waiting in Early Prostate CancerNew England Journal of Medicine, 2002
- Cooperativity between mutations in tyrosine kinases and in hematopoietic transcription factors in AMLLeukemia, 2002
- Gene expression correlates of clinical prostate cancer behaviorPublished by Elsevier ,2002
- Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemiaJournal of Clinical Investigation, 2001
- Delineation of prognostic biomarkers in prostate cancerNature, 2001
- The Polycomb group protein EZH2 is upregulated in proliferating, cultured human mantle cell lymphomaBritish Journal of Haematology, 2001
- Proliferative involvement of ENX‐1, a putative human Polycomb group gene, in haematopoietic cellsBritish Journal of Haematology, 2000
- Transcriptional repression mediated by the human polycomb-group protein EED involves histone deacetylationNature Genetics, 1999